Chimeric Antigen Receptor T cell (CAR-T) therapy has transformed the treatment of hematological malignancies. Autologous CAR-T therapies have shown remarkable efficacy but face multiple challenges, including the need to collect autologous T cell lymphocytes, logistical complexity, prolonged manufacturing time, inadequate quantity due to the collection of already exhausted cells from heavily treated patients, T cell quality not meeting the FDA specifications, and high costs, thereby limiting their widespread use. Allogeneic CAR-T (allo-CAR-T) therapy offers a promising alternative and several advantages, including immediate availability as an off-the-shelf product, standardized production that meets pre-defined quality standards, and potentially reduced costs. However, allo-CAR-T therapies encounter significant challenges, particularly the risk of graft-versus-host disease (GvHD), a clinically observed complication unless mitigating steps are taken, and host immune-mediated rejection, which can compromise their safety and effectiveness. Alternative approaches focus on gene-editing techniques and cell source modifications to maintain the efficacy of alloCAR-Ts in hematologic malignancies while minimizing complications. Techniques such as CRISPR/Cas9-mediated disruption of TCR and HLA genes, the use of γδ T cells, and the overexpression of immunomodulatory proteins like CD47 offer promising strategies for creating safer and more effective CAR-T cell therapies. However, further research and clinical validation are necessary to optimize these approaches and minimize the risk of adverse immune reactions in patients. This review summarizes current advancements in gene editing, the use of CRISPR-Cas9 technology, innovations in lymphodepletion regimens, and strategies for overcoming graft rejection. We also dive into currently approved therapies, ongoing clinical trials, and future directions.
